Russia Plans to Register World's First Coronavirus Vaccine By August

Russia intends to be first to approve Covid-19 vaccine

Russia intends to be first to approve Covid-19 vaccine

Russia could make 30 million doses domestically in 2020 for its first Covid-19 vaccine, and 170 million overseas, with five countries expressing interest in producing the vaccine and others willing to produce it, according to a Bloomberg report quoting Russian Direct Investment Fund's head Kirill Dmitriev.

The adenoviral vector-based vaccine developed by Russian military and government researchers is now in phase 2 trials.

The Russian army said that the vaccine is "ready" after the Phase 1 trials.

Meanwhile, the first phase of Covaxin's human trial was completed at PGIMS Rohtak. "All (trial) results so far are highly positive".

The Russian officials are working towards a date of August 10 or earlier for approval of the vaccine, which has been prepared by the Moscow-based Gamaleya Institute.

"It's a Sputnik moment", Kirill Dmitriev, head of Russia's sovereign wealth fund, which is providing the money for Russian vaccine research, told CNN.

New study claims kids can spread Covid-19 as much adults
At that stage, however, very little was known about how and why the virus affects an infected person's sense of smell. Loss of taste and smell were added to the United Kingdom government's official list of symptoms for COVID-19 in May.

"The Ministry of Health in Russian Federation is following all necessary strict procedures. No corners are being cut", Dmitriev said on Tuesday.

The team also noted that the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in 30,000 participants in September.

Russian scientists explain they have moved quickly because their vaccine is built on an existing vaccine.

"This study shows that even just a single immunization with the Ad26 vaccine leads to neutralizing antibody responses and robust protection of monkeys against COVID-19", said Dr. Dan Barouch, a vaccine researcher at Beth Isreal Deaconness who led the research in collaboration with J&J. The allegations have been denied by Moscow.

Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC, Johnson & Johnson, said: "As we collectively battle this pandemic, we remain deeply committed to our goal of providing a safe and effective vaccine to the world". At least four are in final Phase III human trials, according to World Health Organization data - including three developed in China and another in Britain.

News about the planned approval of the vaccine comes as global confirmed cases of coronavirus hit 16,747,268. We hope that we have succeeded by giving you the full details and information.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.